Zhenbaodao's Subsidiary Receives Approval Notice For Marketing Authorization Application Of Rivaroxaban Active Pharmaceutical Ingredient

Dec 03, 2025

Leave a message

Recently, Jixi Branch of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") has received the "Approval Notice for Marketing Authorization Application of Chemical Active Pharmaceutical Ingredient (API)" issued by the National Medical Products Administration (NMPA) of the People's Republic of China. Relevant matters are hereby announced as follows:

I. Basic Information of the API

Name of Chemical API: Rivaroxaban

Notice No.: 2024YS01171

Registration No.: Y20230000583

Registration Standard No. for Chemical API: YBY74452024

Packaging Specification: 10kg/unit

Validity Period: 24 months

Manufacturer: Jixi Branch of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.

Approval Conclusion: In accordance with the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, this product meets the relevant requirements for drug registration and is approved for registration. The quality standard, labels, and production process shall be implemented in accordance with the attached documents. Validity Period of the Notice: Until November 18, 2029.

II. Other Information of the API

Rivaroxaban is indicated for:

Prophylaxis of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery;

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults; reduction of the risk of recurrent DVT and/or PE in patients who remain at high risk of recurrence after completing at least 6 months of initial treatment for DVT and/or PE;

Reduction of the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) who have one or more risk factors (e.g., congestive heart failure, hypertension, age > 75 years, diabetes mellitus, history of stroke or transient ischemic attack [TIA]).

In July 2023, the Company submitted a technical review application for Rivaroxaban API to the Center for Drug Evaluation (CDE) of the National Medical Products Administration, which was accepted. Recently, the Company obtained the "Approval Notice for Marketing Authorization Application of Chemical API" issued by the NMPA. The status of this API is displayed as "A" on the CDE Registration Information Publicity Platform for APIs, Excipients, and Packaging Materials of the National Medical Products Administration.

Send Inquiry
Contact usif have any question

You can either contact us via phone, email or online form below. Our specialist will contact you back shortly.

Contact now!